Rosuvastatin reduces non-high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia)

Journal of Clinical Lipidology

Volumn 2, Issue 6, 2008, Pages 418-425

  Blom, Dirk J ^a   Marais, A David ^a   Retterstøl, Kjetil ^b   Stein, Evan A ^c   Ycas, Joseph ^d   Gu, Zheng ^d   Miller, Elinor ^d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c Metabolic and Atherosclerosis Research Center   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Dysbetalipoproteinemia; Fibrate; Fredrickson type III hyperlipoproteinemia; Remnant lipoprotein; Rosuvastatin; Statin

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; BEZAFIBRATE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MALE; MULTICENTER STUDY; MYOPATHY; NORWAY; OPEN STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOUTH AFRICA; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; URINALYSIS; VITAL SIGN;

EID: 57549100263     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2008.10.002     Document Type: Article

References (19)

1. Blom D.J., Byrnes P., Jones S., and Marais A.D. Dysbetalipoproteinaemia-clinical and pathophysiological features. S Afr Med J 92 (2002) 892-897
2. Brewer Jr. H.B., Zech L.A., Gregg R.E., Schwartz D., and Schaefer E.J. NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. Ann Intern Med 98 (1983) 623-640
3. Feussner G., Wagner A., Kohl B., and Ziegler R. Clinical features of type III hyperlipoproteinemia: analysis of 64 patients. Clin Investig 71 (1993) 362-366
4. Mahley R.W., and Ji Z.S. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 40 (1999) 1-16
5. Morganroth J., Levy R.I., and Fredrickson D.S. The biochemical, clinical, and genetic features of type III hyperlipoproteinemia. Ann Intern Med 82 (1975) 158-174
6. Smelt A.H., and de Beer F. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects. Semin Vasc Med 4 (2004) 249-257
7. Le N.A., and Walter M.F. The role of hypertriglyceridemia in atherosclerosis. Curr Atheroscler Rep 9 (2007) 110-115
8. Nakamura T., and Kugiyama K. Triglycerides and remnant particles as risk factors for coronary artery disease. Curr Atheroscler Rep 8 (2006) 107-110
9. Walden C.C., and Hegele R.A. Apolipoprotein E in hyperlipidemia. Ann Intern Med 120 (1994) 1026-1036
10. de Villiers W.J., van der Westhuyzen D.R., Coetzee G.A., Henderson H.E., and Marais A.D. The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance. Arterioscler Thromb Vasc Biol 17 (1997) 865-872
11. Mahley R.W., Huang Y., and Rall Jr. S.C. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res 40 (1999) 1933-1949
12. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
13. Leary E.T., Wang T., Baker D.J., et al. Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. Clin Chem 44 (1998) 2490-2498
14. Civeira F., Cenarro A., Ferrando J., et al. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia. Am Heart J 138 (1999) 156-162
15. Feussner G., Eichinger M., and Ziegler R. The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia. Clin Investig 70 (1992) 1027-1035
16. Illingworth D.R., and O'Malley J.P. The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia. Metabolism 39 (1990) 403-409
17. Knopp R.H., Illingworth D.R., Stein E.A., et al. Effect of pravastatin in the treatment of patients with type III hyperlipoproteinemia. Am J Ther 3 (1996) 755-762
18. van Dam M., Zwart M., de Beer F., et al. Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia. Heart 88 (2002) 234-238
19. Stein E.A., Strutt K., Southworth H., Diggle P.J., and Miller E. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 92 (2003) 1287-1293